Detect cognitive decline from speech
- Trial ID
- NCT05765110
- Official Title
- SPEECH as Biomarker for Emotion, Movement and cOgnition in Parkinson's Disease
- Goal
- Detect cognitive decline from speech
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Insel Gruppe AG, University Hospital Bern
- Study Type
- INTERVENTIONAL
- Enrollment
- 80 participants
- Conditions
- Parkinson Disease
- Interventions
- Dopaminergic OFF drug state, DBS OFF state, Dopaminergic ON drug state, DBS ON state
Plain-Language Summary
The team is looking to see whether patterns in speech can serve as an easy, objective biomarker for emotional state, movement symptoms, and cognitive changes in Parkinson's, so doctors could track these aspects more quickly and accurately. Participants have their voice recorded in different clinical states, comparing dopaminergic OFF versus ON (before and after levodopa or similar meds that improve motor symptoms) and DBS OFF versus ON for those with bilateral subthalamic nucleus stimulation, to find which speech features change with medication and DBS effects. The study seeks people with idiopathic PD over 30 and up to 75 years old, fluent in German or French, with or without bilateral STN DBS, normal cognition (MoCA 24 or higher) and no other brain or speech disorders, and also healthy controls aged 50 to 70 with similar language and cognitive requirements.
Locations
- Czech Technical University Prague, Prague, Czechia
- University Hospital Inselspital, Berne, Bern, Switzerland
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Dopaminergic OFF drug state. The team is looking to see whether patterns in speech can serve as an easy, objective biomarker for emotional state, movement symptoms, and cognitive changes in Parkinson's, so doctors could track these aspects more quickly and accurately. Participants have their voice recorded in different clinical states, comparing dopaminergic OFF versus ON (before and after levodopa or similar meds that improve motor symptoms) and DBS OFF versus ON for those with bilateral subthalamic nucleus stimulation, to find which speech features change with medication and DBS effects. The study seeks people with idiopathic PD over 30 and up to 75 years old, fluent in German or French, with or without bilateral STN DBS, normal cognition (MoCA 24 or higher) and no other brain or speech disorders, and also healthy controls aged 50 to 70 with similar language and cognitive requirements.
- Who can participate?
- Participants must be between 30 Years and 75 Years.
- Where is this trial located?
- This trial is recruiting at 2 locations.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 years and 10 months.